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with the PLSF showed a subjective improvement in 
personal well-being for 65% of the patients after 1 and
2 years of GH treatment. Visits to the doctor in the pre-
vious year (from 9.1 ± 1.4 to 3.4 ± 1), days in hospital
(from 7.9 ± 2.6 to 1.6 ± 1.5) and days of sick leave (from
26.4 ± 9.8 to 2.2 ± 1.1) signiﬁcantly decreased during 
GH therapy. Leisure-time physical activity signiﬁcantly
improved during therapy, whereas satisfaction with phy-
sical activity improved only in females. Another gender
difference relates to the need for assistance with daily
activities, which remained low and constant in males, 
but seemed to worsen in females. CONCLUSION: Data
obtained so far conﬁrm that GH replacement therapy
results in a signiﬁcant long-term improvement of both
QoL and general well being and reduction of HCU in 
the Netherlands. Moreover, after two years of GH
therapy both QoL and HCU levels become comparable
to the general Dutch population.
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OBJECTIVES: We report the development of an instru-
ment to assess feelings about self-injection of growth
hormone (GH) in adolescents with growth disorders.
METHODS: Adolescents (age 11–19 years) in 2 cohorts
(UK N = 74 and USA N = 98) completed a 10-item GH
questionnaire, as well as health-related quality of life
(HRQOL), functional status scales, self-control, and self-
esteem scales to assess external validity. The GH and
HRQOL questionnaires were repeated in 2–4 weeks.
RESULTS: The GH questionnaire contains 10 items in 2
subscales (feelings, injection issues) and a total summary
score, with higher scores indicating better acceptance 
of GH. Internal consistency reliabilities were a = 0.77
Summary Score, a = 0.68 Feelings, and a = 0.78 Injection
Issues, with overall test-retest reliability 0.72, and no
ﬂoor or ceiling effects. Signiﬁcant summary score corre-
lations with external validity scales were 0.42 HRQOL,
0.34 functional status, 0.25 self-control. Mean summary
scores did not differ signiﬁcantly by cohort, age, gender,
or diagnosis (range 4.0–4.4 points). The Injection Issues
component was signiﬁcantly associated with all VSP-AM
subscales and total score (all p < 0.01), whereas the Feel-
ings component was signiﬁcantly correlated with self-
esteem, well-being, physical health and the total score (all
p < 0.01) as well as with teachers (p < 0.05). CONCLU-
SIONS: The GH Injection Questionnaire is both a reli-
able and valid measure of attitudes for adolescents with
growth disorders. It measures different constructs than
other instruments. Adolescents who were more comfort-
able with GH injections had higher HRQOL, functional
capacity, and self-control.
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OBJECTIVES: The beneﬁcial effects of growth hormone
(GH) replacement in patients with GH deﬁciency (GHD)
are now well recognized. Moreover, ﬁrst evidence that
these effects are accompanied by a reduction in the use
of healthcare resources has been provided by KIMS, the
Pharmacia International Metabolic Database of adult
GHD patients receiving GH therapy (Genotropin, 
Pharmacia Corp.). The aim of the present study was to
investigate effects of GH replacement in the German
KIMS cohort. METHODS: The analysis was based on
105 patients (65m, 40w) with GHD. 1-year follow-up
was available from all patients, 2-year follow-up from 
60 patients. Statistical analyses were performed with
repeated measurements technique. RESULTS: QoL, mea-
sured by Nottingham Health Proﬁle (NHP) and QoL-
Assessment in GHD Adults (QoL-AGHDA) signiﬁcantly
improved after 1 and 2yrs of GH therapy (NHP distress
index: 5.4 ± 4.4 (mean ± SD), 1yr 3.7 ± 4.2 (p < 0.001),
2yrs 4.1 ± 5.0; QoL-AGHDA score: 9.4 ± 6.3, 1yr 6.4 ±
6.1 (p < 0.001), 2yrs 6.3 ± 6.4 (p < 0.001)). Patient-
reported outcomes were collected with help of Patient
Life Situation Form. 64.0% reported subjective improve-
ment at 1yr, and 78.9% at 2yrs (2nd vs. 1st yr: p < 0.05).
Visits to the doctor per yr (8.2 ± 6.9, 1yr 4.8 ± 7.2 (p <
0.001), 2yrs 3.9 ± 5.0 (p < 0.001)), days in hospital (14.6
± 20.5, 1yr 0.9 ± 3.3 (p < 0.001), 2yrs 0.4 ± 1.8 (p <
0.01)), and days of sick leave (23.8 ± 33.3, 1yr 1.7 ± 3.5
(p < 0.05), 2yrs 3.0 ± 4.2 (p < 0.05)) signiﬁcantly
decreased during GH therapy. Males presented a signiﬁ-
cantly better QoL score in terms of NHP distress index
(p < 0.02). Need for assistance with daily activities
decreased only in females from 30.8% to 19.1%. CON-
CLUSIONS: This country speciﬁc analysis of the German
KIMS cohort conﬁrms signiﬁcant reduction in the use of
healthcare resources as well as signiﬁcant improvements
in QoL and patient reported outcomes during GH
replacement in previously untreated adults with GHD.
Improvements in QoL seem to be more pronounced in
males, whereas females showed a higher reduction of the
need for assistance in daily activities.
